We are dedicated to enhancing cancer treatment by leveraging the microbiome’s potential – the diverse microorganisms within our bodies. While existing therapies like immune checkpoint blockade (ICB) show promise, their effectiveness varies widely among patients. Our project focuses on the translation of innovative microbiome-derived compounds from laboratory to the market to improve ICB therapy outcomes. […]
Read More